Stock Market & Financial Investment News

News Breaks September 24, 2012 08:29 EDT ALXN Alexion price target raised to $132 from $115 at Canaccord Canaccord's physican feedback suggests a high likelihood of of success for Soliris in NMO, Ph 1/2 data expected October 9, and STEC-HUS. Shares are Buy rated. News For ALXN From The Last 14 Days Check below for free stories on ALXN the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 18, 2013 08:36 EDT ALXN Elan shares could be worh $19 in a buyout, says Jefferies Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. June 10, 2013 14:38 EDT ALXN Alexion: Will not present at William Blair conference due to schedule conflict Subscribe for More Information June 5, 2013 17:07 EDT ALXN Alexion says data demonstrates Soliris effective to treat aHUS Alexion Pharmaceuticals announced that data published in the June 6 issue of The New England Journal of Medicine demonstrate that chronic Soliris therapy is effective in the treatment of patients with atypical hemolytic uremic syndrome, or aHUS, a genetic, life-long, ultra-rare disease associated with vital organ failure and premature death. In patients with aHUS, uncontrolled terminal complement activation causes thrombotic microangiopathy, the formation of blood clots in small blood vessels throughout the body. Soliris was approved for the treatment of patients with aHUS in the United States, Europe and other countries based on data from the two prospective studies published in NEJM, together with data from a separate retrospective study. Sign up for a free trial to see the rest of the stories you've been missing.